Therefore, based on our research, the development of anti-tumor small molecule inhibitors targeting BRD7/c-Myc axis could be an attractive approach in solving the problem of c-Myc “undruggable” and the clinical targeted therapy of CRC. Here, MYC is linked to neoplasm.